Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 3,618 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Intestinal Cancer Clear all
Recruiting No phase listed Observational

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

NCT04075305
View directory record Official record
Conditions
Oncology, Breast Cancer, Prostate Cancer, Gynecologic Cancer, Brain Tumor, Brain Cancer, Gynecologic Tumor, Prostate Tumor, Prostate Neoplasm, Breast Tumor, Radiation Toxicity, Quality of Life, Rectal Cancer, Rectal Tumor, Rectal Neoplasms, Lung Cancer, Lung Tumor, Lung Neoplasm, Esophageal Cancer, Esophagus Cancer, Esophageal Tumor, Esophageal Neoplasm, Esophagus Tumor, Esophagus Neoplasm, Pancreatic Cancer, Pancreatic Tumor, Pancreatic Neoplasms, Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Tumor, Tumor, Neoplasms, Bladder Cancer, Bladder Neoplasm, Liver Cancer, Liver Neoplasms, Liver Metastases, Oligometastases
Interventions
Radiation therapy
Radiation
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania • Houston, Texas • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 25, 2026, 7:52 AM EDT
Terminated Phase 1 Interventional

OSI-906 and Irinotecan in Patients With Advanced Cancer

NCT01016860
View directory record Official record
Conditions
Colorectal Cancer
Interventions
OSI-906, irinotecan
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 21, 2013 · Synced Oct 25, 2026, 7:52 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

NCT05789069
View directory record Official record
Conditions
Renal Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer, Gastric Cancer, Colorectal Cancer
Interventions
HFB200603, Tislelizumab
Drug
Lead sponsor
HiFiBiO Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Philadelphia, Pennsylvania • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 25, 2026, 7:52 AM EDT
Completed No phase listed Observational

Chromogranin A as Blood Marker in Cancer Patients

NCT03817866
View directory record Official record
Conditions
Gastric Neoplasms, Pancreatic Neoplasms, Small Intestinal Neoplasms, Colorectal Neoplasms
Interventions
BRAHMS CgA II KRYPTOR
Diagnostic Test
Lead sponsor
Brahms AG
Industry
Eligibility
18 Years to 85 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Palo Alto, California • Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 25, 2026, 7:52 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed

NCT03890731
View directory record Official record
Conditions
Solid Cancer
Interventions
BAY73-4506 (Regorafenib, Stivarga)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 25, 2026, 7:52 AM EDT
Terminated Phase 1 Interventional

Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib

NCT02538627
View directory record Official record
Conditions
Colorectal Cancer, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Interventions
MM-151, MM-121, MM-141, trametinib
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Aurora, Colorado • Sandy Springs, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 25, 2026, 7:52 AM EDT
Not yet recruiting Phase 1 Interventional

Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy

NCT07715903
View directory record Official record
Conditions
Colorectal Neoplasms, Neoplasms, Intrahepatic Cholangiocarcinoma, Adrenocortical Carcinoma, Metastasis, Neoplasm
Interventions
Carfilzomib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 25, 2026, 7:52 AM EDT
Completed Phase 1 Interventional Results available

Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)

NCT03374254
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Pembrolizumab, Binimetinib, Oxaliplatin, Leucovorin, 5-Fluorouracil [5-FU], Irinotecan
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
10
States / cities
Duarte, California • Aurora, Colorado • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 25, 2026, 7:52 AM EDT
Recruiting Phase 1Phase 2 Interventional

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

NCT03190941
View directory record Official record
Conditions
Pancreatic Cancer, Gastric Cancer, Gastrointestinal Cancer, Colon Cancer, Rectal Cancer
Interventions
Cyclophosphamide, Fludarabine, Anti-KRAS G12V mTCR PBL, Aldesleukin
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 25, 2026, 7:52 AM EDT
Not listed No phase listed Observational

Molecular Determinants of Response to Preoperative Therapy in Patients With Locally Advanced Colorectal Cancer

NCT02877056
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Endoscopy
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 25, 2026, 7:52 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer

NCT00019474
View directory record Official record
Conditions
Extrahepatic Bile Duct Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Liver Cancer, Pancreatic Cancer, Small Intestine Cancer
Interventions
filgrastim, recombinant interferon alfa, fluorouracil, hydroxyurea
Biological · Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Oct 25, 2026, 7:52 AM EDT
Terminated Phase 1 Interventional Results available

Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer

NCT00006046
View directory record Official record
Conditions
Colorectal Cancer
Interventions
monoclonal antibody hu3S193
Biological
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 25, 2026, 7:52 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The PRIME-CRC Trial to Promote CRC Screening in Rural Communities

NCT04313114
View directory record Official record
Conditions
Colorectal Cancer
Interventions
health literacy appropriate education and demonstration, shared decision making, automated call reminders or automated texts
Behavioral
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
45 Years to 75 Years
Enrollment
804 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
3
States / cities
Bastrop, Louisiana • Marion, Louisiana • Saint Joseph, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 25, 2026, 7:52 AM EDT
Terminated Phase 2 Interventional Results available

LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma

NCT03287947
View directory record Official record
Conditions
Appendix Cancer
Interventions
nintedanib
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 25, 2026, 7:52 AM EDT
Terminated No phase listed Observational

Improving Health of Patients With Colon Cancer Following Surgery: A Trial of SA-ICAN Via Videoconferencing

NCT02301338
View directory record Official record
Conditions
Colon Cancer
Interventions
Usual care, Phone Calls
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
65 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 25, 2026, 7:52 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

NCT04430738
View directory record Official record
Conditions
Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
Interventions
tucatinib, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 25, 2026, 7:52 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors

NCT00003038
View directory record Official record
Conditions
Adrenocortical Carcinoma, Breast Cancer, Colorectal Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
doxorubicin hydrochloride, suramin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Oct 25, 2026, 7:52 AM EDT
Completed Phase 2 Interventional Results available

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

NCT00803647
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
cetuximab, 5-FU, oxaliplatin, leucovorin
Biological · Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
23
States / cities
Loma Linda, California • Orange, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 25, 2026, 7:52 AM EDT
Not listed Phase 1Phase 2 Interventional

CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab

NCT05121038
View directory record Official record
Conditions
Colon Cancer, Pancreas Cancer, Digestive Cancer
Interventions
CEND-1, Panitumumab, Folfirinox
Drug
Lead sponsor
Anup Kasi
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Fairway, Kansas • Kansas City, Kansas • North Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Oct 25, 2026, 7:52 AM EDT
Completed No phase listed Observational

Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)

NCT02503696
View directory record Official record
Conditions
Inflammatory Bowel Disease, Colorectal Neoplasms, Digestive System Diseases, Colonic Diseases, Colorectal Cancer
Interventions
Stool Collection Kit
Device
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
18 Years to 84 Years
Enrollment
697 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
27
States / cities
Dothan, Alabama • La Jolla, California • Mission Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 25, 2026, 7:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Screen to Save: NCI Colorectal Cancer Outreach & Screening Initiative

NCT05064410
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Educational Intervention
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
45 Years to 75 Years
Enrollment
188 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 25, 2026, 7:52 AM EDT
Active, not recruiting No phase listed Observational

An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis

NCT02808780
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
16
States / cities
Murrieta, California • Rialto, California • Ventura, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 7:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Increasing Uptake of Evidence-Based Screening Services Through CHW-led Multi-modality Intervention

NCT02970136
View directory record Official record
Conditions
Human Papillomavirus, Human Immunodeficiency Virus, Hepatitis C, ColoRectal Cancer
Interventions
OraQuick Swab, Fecal Immunochemical Test, OraQuick Fingerstick, Standard Screening Tests, HPV Self-Sampling Test, Home Based Screening Tests
Device · Other
Lead sponsor
University of Miami
Other
Eligibility
50 Years to 64 Years
Enrollment
754 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 28, 2021 · Synced Oct 25, 2026, 7:52 AM EDT
Completed Phase 1 Interventional Results available

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

NCT02009449
View directory record Official record
Conditions
Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, Non-small Cell Lung Carcinoma, Solid Tumors, Breast Cancer
Interventions
Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil), gemcitabine/nab-paclitaxel, Capecitabine, Pazopanib, Pembrolizumab, Paclitaxel, nivolumab, Gemcitabine/carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 25, 2026, 7:52 AM EDT